| Autor: |
Jones R; Department of Hepatology, Leeds Teaching Hospitals NHS Trust, St James' University Hospital, Leeds, UK., Phillips S; Foundation for Liver Research, The Roger Williams Institute of Hepatology, London, UK., Elsharkawy A; Department of Hepatology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK., Singhal S; Department of Gastroenterology, Sandwell and West Birmingham Hospitals NHS Trust, Sandwell General Hospital, West Bromwich, UK., Leithead J; Department of Gastroenterology and Hepatology, Forth Valley Royal Hospital, Larbert, UK., Chokshi S; Foundation for Liver Research, The Roger Williams Institute of Hepatology, London, UK., Towey J; Department of Hepatology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK., Subhani M; Gastrointestinal and Liver Disorders, Nottingham University Queen's Medical Centre, Nottingham, UK., Wood C; Department of Gastroenterology and Hepatology, Royal Cornwall Hospital NHS Trust, Truro, UK., Davidson K; Department of Pharmacy, NHS Lothian, Edinburgh, UK., Kooner E; Department of Gastroenterology and Hepatology, East and North Hertfordshire NHS Trust, Lister Hospital, Stevenage, UK., Aithal G; Gastrointestinal and Liver Disorders, Nottingham University Queen's Medical Centre, Nottingham, UK., Oben JA; Department of Gastroenterology and Hepatology, King's College London, Guy's and St Thomas' Hospital, London SE1 7EH, UK. Electronic address: jude.1.oben@kcl.ac.uk. |
| Abstrakt: |
Competing Interests: GA has been an adviser to GlaxoSmithKline, AstraZeneca, Pfizer, Benevolent AI Bio, Puretech, Merck Healthcare, Servier, Clinpace, Amryth, NuCana, DNAi, and Albireo. All other authors declare no competing interests. |
